Poll: Lipoprotein(a): What is Your Clinical Practice?
Elevated Lipoprotein(a) [Lp(a)] is one of the leading inherited dyslipidemias associated with premature atherosclerotic cardiovascular disease (ASCVD) including coronary artery disease or ischemic stroke.1,2 High plasma Lp(a) concentrations are also associated with aortic stenosis.3
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol 2019;73:3168-3209.
- Authors/Task Force Members, ESC Committee for Practice Guidelines, ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205.
- Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019;13:374-92.
Keywords: Primary Prevention, Lipoprotein(a), Dyslipidemias, Plaque, Atherosclerotic, Coronary Artery Disease, Stroke, Aortic Valve Stenosis
< Back to Listings